Clinical Trial Search

Primary: Number of Subjects Monitored for Long-term Safety of PA32540 — 379 participants

Primary: Frequency of Adverse Events — 12; 15; 1; 0 participants

Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005

Primary: Percentage of Participants With Hb Levels Within 11.0-12.5 Grams Per Deciliter (g/dL) During Evaluation Phase — 31.7 percentage of participants

Primary: Progression-Free Survival (Site Read, Investigator Assessment) — 98; 107 Patients with a progression event — p=0.273

Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014

Primary: SVR12 Rates With Historical Control — 79.95; 76.68; 88.28; 70.78 percentage of participants — p=<0.0001

Primary: Number of Subjects With an sUA Level That is < 6.0 mg/dL — 32; 2 Number of Subjects — p=<0.0001

Primary: Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu) — 50.6; 42.4 percentage of participants — p=0.076

Primary: Overall Survival — 4.9; 4.2; 6.1; 4.2 months — p=0.9416

Primary: FEV1 AUC (0-12h) Change From Patient Baseline After 6 Weeks of Treatment — 0.295; 0.317; 0.192; 0.188 Litres — p=<0.0001

Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001

Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 100.0; 66.0 percentage of participants — p=<0.001

Primary: Number of Subjects With Vaccine Response to Anti-gE Antibodies — 366 Subjects